Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization

- Bristol Myers Squibb (BMS) has ended its collaboration with Eisai on an antibody-drug conjugate (ADC) due to portfolio prioritization efforts.
- Eisai will now assume sole responsibility for the development of the ADC, which targets the folate receptor alpha (FRα).
- BMS originally paid $650 million upfront in 2021 for the collaboration.
- The decision to end the collaboration is part of BMS' ongoing portfolio prioritization efforts.
- Eisai will continue the development of farletuzumab ecteribulin, the ADC in question, independently.